Annexon, Inc. is a clinical-stage biopharmaceutical company based in Brisbane, California, that develops therapies for autoimmune, neurodegenerative, and ophthalmic disorders. The company's proprietary platform targets the C1q molecule to block the classical complement pathway and prevent tissue-damaging neuroinflammation. Its lead clinical candidates include ANX005, an investigational monoclonal antibody for the treatment of Guillain-Barré Syndrome, and ANX007, an antigen-binding fragment in development for geographic atrophy. The company is also advancing ANX1502, an oral small molecule inhibitor, and ANX009 for lupus nephritis. By focusing on the initiating molecule of the classical complement pathway, Annexon aims to provide targeted treatments for serious neuroinflammatory diseases of the body, brain, and eye.
